Biotechnology
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 660.53 | 566.09 | 535.80 | 510.69 | 449.63 |
Total Expenses | 457.58 | 421.64 | 364.75 | 300.56 | 270.47 |
Profit Before Tax | 187.82 | 140.39 | 171.06 | 210.13 | 179.16 |
Profit After Tax | 136.95 | 103.87 | 123.80 | 151.29 | 133.05 |
Operating Profit after Depreciation | 205.88 | 146.87 | 172.85 | 211.74 | 182.19 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 660.11 | 654.94 | 624.55 | 609.56 | 568.25 |
Total Non Current Assets | 725.72 | 699.74 | 663.17 | 640.16 | 603.03 |
Total Current Assets | 809.74 | 722.11 | 604.44 | 516.01 | 375.57 |
TOTAL ASSETS | 1,535.46 | 1,421.85 | 1,267.61 | 1,156.17 | 978.61 |
Total Shareholder's Fund | 1,324.13 | 1,235.07 | 1,088.59 | 970.94 | 839.65 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 141.37 | 140.36 | 122.29 | 162.97 | 140.90 |
Net Cash used in Investing Activities | -64.80 | -285.50 | 1.65 | -27.33 | -42.74 |
Net Cash used in Financing Activities | -59.24 | -25.80 | -48.50 | -26.39 | -38.55 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 424.28 | 321.34 | 281.88 | 290.30 | 256.36 |
Total Expenses | 271.34 | 247.06 | 209.81 | 191.87 | 180.50 |
Profit Before Tax | 133.99 | 74.28 | 72.07 | 98.43 | 75.85 |
Profit After Tax | 108.12 | 55.53 | 54.51 | 71.01 | 57.95 |
Operating Profit after Depreciation | 153.10 | 74.41 | 72.17 | 98.53 | 76.95 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 147.54 | 148.28 | 137.46 | 137.60 | 132.33 |
Total Non Current Assets | 384.59 | 386.26 | 352.94 | 329.37 | 297.31 |
Total Current Assets | 248.34 | 189.54 | 176.69 | 160.23 | 125.36 |
TOTAL ASSETS | 632.93 | 575.80 | 529.62 | 489.60 | 422.68 |
Total Shareholder's Fund | 580.47 | 525.33 | 480.35 | 435.45 | 370.48 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 55.81 | 50.30 | 37.10 | 84.23 | 45.98 |
Net Cash used in Investing Activities | -6.88 | -42.35 | -14.24 | -69.91 | -24.94 |
Net Cash used in Financing Activities | -56.88 | -11.99 | -10.87 | -15.49 | -18.56 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 146.10 | 154.52 | 157.82 | 160.94 | 157.84 |
Total Expenses | 103.68 | 103.36 | 102.44 | 107.18 | 106.53 |
Profit Before Tax | 42.21 | 48.67 | 39.62 | 58.88 | 47.93 |
Profit After Tax | 33.39 | 34.98 | 29.87 | 42.50 | 35.20 |
Operating Profit after Depreciation | 52.04 | 58.15 | 64.88 | 68.16 | 57.41 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 77.38 | 85.96 | 92.40 | 91.14 | 96.58 |
Total Expenses | 63.86 | 65.04 | 63.16 | 66.59 | 69.96 |
Profit Before Tax | 12.32 | 72.16 | 10.38 | 25.36 | 24.77 |
Profit After Tax | 9.13 | 67.06 | 3.14 | 19.12 | 18.38 |
Operating Profit after Depreciation | 15.18 | 74.80 | 32.45 | 28.12 | 27.41 |
₹1.1/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Advanced Enzyme Technologies Ltd | ₹329.95 | ₹3,691.50 |
Sun Pharmaceuticals Industries Ltd | ₹1,745.25 | ₹4,18,743.94 |
Divis Laboratories Ltd | ₹5,733.60 | ₹1,52,209.07 |
Cipla Ltd | ₹1,458.15 | ₹1,17,762.24 |
Torrent Pharmaceuticals Ltd | ₹3,357.15 | ₹1,13,616.11 |
Mankind Pharma Ltd | ₹2,488.40 | ₹1,02,663.15 |
05 Dec 2024, 12:56 pm
11 Nov 2024, 01:57 pm
02 Nov 2024, 01:55 pm
31 Oct 2024, 01:02 pm
03 Aug 2024, 02:32 pm